Therapy Areas: Oncology
Day One completes Mersana acquisition to add rare cancer antibody drug conjugate
6 January 2026 - US-based biopharmaceutical company Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN) announced on Tuesday that it has completed its acquisition of Mersana Therapeutics, Inc. (NASDAQ: MR...
Cartography Biosciences partners with Pfizer to discover tumour-selective antigens
6 January 2026 - Biotechnology company Cartography Biosciences Inc announced on Tuesday that it has entered a multi-year collaboration with biopharmaceutical company Pfizer Inc (NYSE:PFE) to discover ...
BostonGene and AstraZeneca collaborate to advance AI-driven oncology development
6 January 2026 - Biomedical software company BostonGene Corporation announced on Tuesday that it has agreed a strategic collaboration with biopharmaceutical company AstraZeneca plc (STO:AZN) (LON:AZN)...
RedHill advances RHB-102 across GI indications
5 January 2026 - Biopharmaceutical company RedHill Biopharma Ltd (Nasdaq: RDHL) revealed on Monday that development of RHB-102 (Bekinda) is progressing across multiple gastrointestinal indications, in...
Kelun-Biotech lung cancer drug granted Breakthrough Therapy Designation in China
5 January 2026 - Chinese biopharmaceutical company Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG: 6990), a subsidiary of Kelun Pharmaceutical (SHE: 002422), said on Monday that its TROP2-dire...
BioInvent reports encouraging Phase 2a data for BI-1808 plus pembrolizumab in recurrent ovarian cancer
5 January 2026 - Swedish biotech company BioInvent International AB (STO:BINV) on Monday reported encouraging interim data from an ongoing Phase 2a study evaluating BI-1808, a novel immuno-oncology ca...